Pfizer’s 20-Valent Vaccine And Prevnar Successor Succeeds In Phase III
The company still plans to file 20vPnC for US FDA approval by the end of 2020 after the pneumococcal vaccine was non-inferior to Prevnar and to Pneumovax on six additional serotypes in older patients.
You may also be interested in...
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
The view from 2020: Scrip looks back at the most successful commercial launches of the decade.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.